francisco jose moya torrecilla

Dr. francisco jose moya torrecilla

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
IMIvan Medina-Porqueres
Ivan Medina-Porqueres
PMPablo Martin-Garcia
Pablo Martin-Garcia
SSSofia Sanz-De-Diego
Sofia Sanz-De-Diego
AGAbel Gomez-Caceres
Abel Gomez-Caceres
FTfrancisco jose moya torrecilla
francisco jose moya torrecilla
DVDANIEL CANDIDO ROSADO VELAZQUEZ
DANIEL CANDIDO ROSADO VELAZQUEZ
Meniscal injuries are among the most frequently encountered conditions in the knee joint. Therapeutic approaches are diverse and are largely dependent on the extent and location of the injury. The purpose of this study was to describe the clinical and functional outcomes of an intraarticular and percutaneous platelet-rich plasma (PRP) injection regime in patients with stable meniscal injuries. Demographics, the type of tear, affected knee, surgical procedure, type of intervention, follow-up period, and outcomes were recorded in all cases. Patient-reported outcome measures included the Knee Injury and Osteoarthritis Outcome Score (KOOS) and Tegner activity level scale. Overall patient satisfaction, quality of life, and pain intensity were also assessed. A total of 38 cases (8 females) had sustained a stable meniscal lesion (32 medial, 6 lateral) and met the inclusion criteria. All of them received three intraarticular and percutaneous PRP injections. Patients receiving the PRP injection regime reported clinically (p = 0.000) and functionally (p = 0.000 and p = 0.001) significant improvement in all outcome measures during this interval. All patients reported they were very satisfied or satisfied with the outcome. The results of this study suggest that the treatment of stable meniscal injuries with percutaneous–intraarticular PRP injections can achieve a significant clinical and functional improvement.

26 April 2024 in Biomedicines
Verified
Journal Article
Open access
PDF file
IMIvan Medina-Porqueres
Ivan Medina-Porqueres
PMPablo Martin-Garcia
Pablo Martin-Garcia
SSSofia Sanz-De-Diego
Sofia Sanz-De-Diego
MRMarcelo Reyes-Eldblom
Marcelo Reyes-Eldblom
FTfrancisco jose moya torrecilla
francisco jose moya torrecilla
AGAbel Gomez-Caceres
Abel Gomez-Caceres
The platelet-rich plasma (PRP) approach may be an effective treatment for joint and cartilage pathologies. However, the rationale for its effectiveness on joint instability is limited. This study aimed to assess the safety and effectiveness of PRP injections in patients with chronic lateral ankle instability (CLAI). This retrospective study was performed at a single-center outpatient clinic between January 2015 and February 2023 and included pre-intervention assessment and short-term follow-up. Patients were excluded if they had received previous surgical treatment or had constitutional hyperlaxity, systemic diseases, or grade II or III osteoarthritis. The clinical and functional evaluation consisted of the Karlsson score, the Cumberland Ankle Instability Tool (CAIT), Good’s grading system, the patient’s subjective satisfaction level, and the time required to return to exercise. The entire PRP therapy regime consisted of three PRP administrations at 7-day intervals and follow-up appointments. PRP was administered both intraarticularly and into talofibular ligaments. A total of 47 consecutive patients with CLAI were included, 11 were female (23.4%), with a mean age at intervention of 31.19 ± 9.74 years. A statistically significant improvement was found in the CAIT and Karlsson scores at 3 months (27.74 ± 1.68 and 96.45 ± 4.28, respectively) relative to the pre-intervention status (10.26 ± 4.33 and 42.26 ± 14.9, respectively, p < 0.000). The mean follow-up of patients with CLAI was 17.94 ± 3.25 weeks. This study represents successful short-term functional and clinical outcomes in patients with CLAI after PRP treatment, with no adverse effects. It demonstrates the feasibility of a randomized controlled trial to further assess this therapy.

Verified
Journal Article
Open access
PDF file
FTfrancisco jose moya torrecilla
francisco jose moya torrecilla
GCGemma Álvarez Corral
Gemma Álvarez Corral
EPEva Gutiérrez Pérez
Eva Gutiérrez Pérez
DMDaniel Morell-Garcia
Daniel Morell-Garcia
JPJuan Ortega Pérez
Juan Ortega Pérez
FRFrancisco Temboury Ruiz
Francisco Temboury Ruiz
Objective: To evaluate the economic impact associated with the use of specific brain biomarkers glial fibrillary acid protein (GFAP) and ubiquitin C-terminal hydrolase L1 (UCH-L1) in adult patients with suspected mild traumatic brain injury (TBI) in a standard Spanish hospital setting. Methods: We used a budget impact analysis (BIA) to compare the cost of standard of care using head computed tomography (CT) to evaluate intracranial injury with a scenario incorporating specific biomarkers GFAP and UCH-L1 in an estimated population of 3500 adult patients attending the hospital emergency department with a score of 13 to 15 on the Glasgow Coma Scale (GCS). The probabilities associated with clinical procedures were obtained from a multidisciplinary group of experts from Spanish hospitals and supplemented with data from the literature. Costs were estimated using hospital tariffs from the Spanish autonomous communities and other official sources. Results: The incorporation of specific biomarkers GFAP and UCH-L1 in the management of mild TBI could generate an estimated annual savings of EUR 696,634 in a standard Spanish hospital, mainly due to reduced CT use. The average savings per patient would be EUR 199.04, and the care time would be reduced by 111 min. Sensitivity analysis, with variations of ±20% in the parameters, confirms these savings. Conclusions: This study suggests that the use of specific biomarkers GFAP and UCH-L1 in the management of mild TBI patients in Spain could reduce the average cost per patient, generating significant savings for hospitals. Future studies that incorporate data from clinical records will help validate these results.

6 May 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
FTfrancisco jose moya torrecilla
francisco jose moya torrecilla
GCGemma Álvarez Corral
Gemma Álvarez Corral
EPEva Gutiérrez Pérez
Eva Gutiérrez Pérez
DMDaniel Morell-Garcia
Daniel Morell-Garcia
JPJuan Ortega Pérez
Juan Ortega Pérez
FRFrancisco Temboury Ruiz
Francisco Temboury Ruiz
Objective: To evaluate the economic impact associated with the use of specific brain biomarkers glial fibrillary acid protein (GFAP) and ubiquitin C-terminal hydrolase L1 (UCH-L1) in adult patients with suspected mild traumatic brain injury (TBI) in a standard Spanish hospital setting. Methods: We used a budget impact analysis (BIA) to compare the cost of standard of care using head computed tomography (CT) to evaluate intracranial injury with a scenario incorporating specific biomarkers GFAP and UCH-L1 in an estimated population of 3,500 adult patients attending the hospital emergency department with a score of 13 to 15 on the Glasgow Coma Scale (GCS). The probabilities associated with clinical procedures were obtained from a multidisciplinary group of experts from Spanish hospitals and supplemented with data from the literature. Costs were estimated using hospital tariffs from the Spanish autonomous communities and other official sources. Results: The incorporation of specific biomarkers GFAP and UCH-L1 in the management of mild TBI could generate estimated annual savings of €696,634 in a standard Spanish hospital, mainly due to reduced CT use. The average saving per patient would be €199.04, and the care time would be reduced by 111 minutes. Sensitivity analysis, with variations of ±20% in the parameters, confirms these savings. Conclusions: This study suggests that the use of specific biomarkers GFAP and UCH-L1 in the management of mild TBI patients in Spain could reduce the average cost per patient, generating significant savings for hospitals. Future studies that incorporate data from clinical records will help validate these results.